UA40621C2 - Моноклональне антитіло, гібридомна клітинна лінія, поліпептид (варіанти), фрагмент днк (варіанти), фармацевтична композиція, спосіб одержання моноклонального антитіла - Google Patents

Моноклональне антитіло, гібридомна клітинна лінія, поліпептид (варіанти), фрагмент днк (варіанти), фармацевтична композиція, спосіб одержання моноклонального антитіла

Info

Publication number
UA40621C2
UA40621C2 UA95125376A UA95125376A UA40621C2 UA 40621 C2 UA40621 C2 UA 40621C2 UA 95125376 A UA95125376 A UA 95125376A UA 95125376 A UA95125376 A UA 95125376A UA 40621 C2 UA40621 C2 UA 40621C2
Authority
UA
Ukraine
Prior art keywords
monoclonal antibody
variants
cell line
hybridoma cell
antibody
Prior art date
Application number
UA95125376A
Other languages
English (en)
Russian (ru)
Inventor
Франческ Мітжанс
Франческ Митжанс
Жом П'юлатс
Жом Пъюлатс
Елізабет Розель
Элизабет Розель
Жом Адан
Саймон Гудмен
Діан Хан
Диан Хан
Original Assignee
Мерк Патент Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8216547&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA40621(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Мерк Патент Гмбх filed Critical Мерк Патент Гмбх
Publication of UA40621C2 publication Critical patent/UA40621C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Даний винахід належить до нового моноклонального антитіла і гібридомної клітинної лінії, яка продукує зазначене антитіло. Крім того, метою даного винаходу є гібридомна клітинна лінія, що продукує моноклональне антитіло, позначене як 272-17Е6 і задепоноване під реєстраційним номером DS M ACC2160, а також моноклональне антитіло, що має зазначені раніше властивості, яке можна одержати за допомогою зазначеної гібридомної клітинної лінії. Більше того, даний винахід стосується ДНК послідовностей і амінокислотних послідовностей. ДНК послідовності кодують антитіло або його частину. Ці послідовності представлені на фіг. 17a і 17b і в прикладеному описі послідовностей. І, нарешті, метою даного винаходу є фармацевтична композиція, що містить визначене раніше антитіло.
UA95125376A 1994-12-20 1995-12-19 Моноклональне антитіло, гібридомна клітинна лінія, поліпептид (варіанти), фрагмент днк (варіанти), фармацевтична композиція, спосіб одержання моноклонального антитіла UA40621C2 (uk)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP94120165 1994-12-20

Publications (1)

Publication Number Publication Date
UA40621C2 true UA40621C2 (uk) 2001-08-15

Family

ID=8216547

Family Applications (1)

Application Number Title Priority Date Filing Date
UA95125376A UA40621C2 (uk) 1994-12-20 1995-12-19 Моноклональне антитіло, гібридомна клітинна лінія, поліпептид (варіанти), фрагмент днк (варіанти), фармацевтична композиція, спосіб одержання моноклонального антитіла

Country Status (26)

Country Link
US (1) US5985278A (uk)
EP (1) EP0719859B1 (uk)
JP (1) JP3898245B2 (uk)
KR (1) KR100450368B1 (uk)
CN (1) CN1117763C (uk)
AR (1) AR001778A1 (uk)
AT (1) ATE244306T1 (uk)
AU (1) AU710234B2 (uk)
BR (1) BR9505980B1 (uk)
CA (1) CA2165573C (uk)
CO (1) CO4480042A1 (uk)
CZ (1) CZ290477B6 (uk)
DE (1) DE69531187T2 (uk)
DK (1) DK0719859T3 (uk)
ES (1) ES2202336T3 (uk)
FI (1) FI118536B (uk)
HU (1) HU221061B1 (uk)
NO (1) NO321186B1 (uk)
PL (1) PL182961B1 (uk)
PT (1) PT719859E (uk)
RU (1) RU2205223C2 (uk)
SI (1) SI0719859T1 (uk)
SK (1) SK284932B6 (uk)
TR (1) TR199501614A2 (uk)
UA (1) UA40621C2 (uk)
ZA (1) ZA9510806B (uk)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4134497A (en) * 1996-09-03 1998-03-26 Chugai Seiyaku Kabushiki Kaisha Anti-integrin alpha3 antibody complexes
ES2321991T3 (es) * 1996-12-09 2009-06-15 Merck Patent Gmbh Receptor de adhesion alfavbet3 recombinante soluble.
EP0996460B1 (en) * 1997-08-08 2005-01-12 The Regents of the University of California Treatment of kidney fibrosis with antibodies against integrin alpha-v-beta 6
DE69930723T2 (de) * 1998-01-23 2006-11-16 Merck Patent Gmbh Verwendung des antikörpers 271.14d9.f8 (dsm acc2331) um die bindung zwischen alphavbeta6-integrin und fibronectin in vitro zu hemmen
US6160099A (en) * 1998-11-24 2000-12-12 Jonak; Zdenka Ludmila Anti-human αv β3 and αv β5 antibodies
US6521593B1 (en) * 1999-02-01 2003-02-18 Childrens Hospital Los Angeles Methods for inhibiting brain tumor growth
US7064180B2 (en) 2000-07-31 2006-06-20 The General Hospital Corporation High affinity integrin polypeptides and uses thereof
US7323552B2 (en) * 2000-07-31 2008-01-29 The General Hospital Corporation Variant integrin polypeptides and uses thereof
US7153944B2 (en) * 2000-07-31 2006-12-26 The General Hospital Corporation High affinity integrin polypeptides and uses thereof
US7163681B2 (en) 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
AU2002306651B2 (en) * 2001-03-02 2007-12-13 Medimmune, Llc Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav Beta3 antagonists
ES2366775T3 (es) 2001-04-24 2011-10-25 Merck Patent Gmbh POLITERAPIA UTILIZANDO AGENTES ANTIANGIOGÉNICOS Y TNF(alfa).
EP1414491A4 (en) * 2001-07-09 2005-07-06 Elan Pharm Inc METHOD OF INHIBITING THE TOXICITY OF AMYLOID
US7829087B2 (en) * 2001-07-09 2010-11-09 Elan Pharmaceuticals, Inc. Methods of treating cognitive impairment
CA2478239A1 (en) * 2002-03-04 2003-09-18 Medimmune, Inc. The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents
JP2005525368A (ja) * 2002-03-04 2005-08-25 メディミューン，インコーポレーテッド インテグリンαｖβ３アンタゴニストをＨＭＧ−ＣｏＡ還元酵素阻害剤またはビスフォスフォネートと併用投与する障害の予防または治療方法
CN100509851C (zh) * 2002-03-13 2009-07-08 拜奥根Idec马萨诸塞公司 抗αvβ6抗体
CN1646160A (zh) 2002-03-13 2005-07-27 拜奥根Idec马萨诸塞公司 抗αvβ6抗体
EP1492870A4 (en) * 2002-04-12 2005-08-03 Raven Biotechnologies Inc ANTIBODIES BINDING TO INTEGRIN-ALPHA-V-BETA-6 AND METHOD OF USE THEREOF
JP2005535572A (ja) * 2002-04-12 2005-11-24 メディミューン，インコーポレーテッド 組換え抗インターロイキン−９抗体
WO2004066956A2 (en) * 2003-01-30 2004-08-12 Medimmune, Inc. Uses of integrin alphavbeta3 antagonists
KR20110094361A (ko) * 2003-04-11 2011-08-23 메디뮨 엘엘씨 재조합 ｉｌ­９ 항체 및 그의 용도
US7351739B2 (en) * 2004-04-30 2008-04-01 Wellgen, Inc. Bioactive compounds and methods of uses thereof
WO2006047639A2 (en) 2004-10-27 2006-05-04 Medimmune, Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
CN102875681A (zh) 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 抗-αvβ6抗体及其用途
CA2646611A1 (en) 2006-03-21 2008-05-22 Genentech, Inc. Combinatorial therapy
SG173364A1 (en) 2006-07-10 2011-08-29 Biogen Idec Inc Compositions and methods for inhibiting growth of smad4-deficient cancers
CA2657581A1 (en) 2006-07-11 2008-01-17 Roy C. Levitt Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors
US8940683B2 (en) 2006-08-10 2015-01-27 Roy C. Levitt Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors
US20090196913A1 (en) * 2007-05-11 2009-08-06 Ken Shi Kun Huang Anti-Alpha-V Immunoliposome Composition, Methods, and Uses
US20090175784A1 (en) * 2007-05-11 2009-07-09 Joshua Goldstein Anti-Alpha V Immunoliposome Composition, Methods, and Uses
EP2526967A1 (en) 2007-07-17 2012-11-28 Merck Patent GmbH Engineered anti-alpha v-integrin hybrid antibodies
US7973138B2 (en) 2007-09-26 2011-07-05 Genentech, Inc. Antibodies
CA2747937C (en) 2008-12-23 2019-02-26 Merck Patent Gmbh Biomarkers for inhibitors with anti-angiogenic activity
JP6051048B2 (ja) 2009-03-25 2016-12-21 ジェネンテック， インコーポレイテッド 新規な抗α５β１抗体及びその使用
AU2010318323A1 (en) 2009-11-13 2012-06-28 Merck Patent Gmbh Anti integrin antibodies linked to nanoparticles loaded with chemotherapeutic agents
SG183356A1 (en) * 2010-02-18 2012-09-27 Univ California INTEGRIN aVß8 NEUTRALIZING ANTIBODY
WO2012027745A1 (en) * 2010-08-27 2012-03-01 University Of Miami Treatment of renal diseases
WO2012107211A1 (en) 2011-02-11 2012-08-16 Merck Patent Gmbh Anti-alpha-v integrin antibody for the treatment of prostate cancer
EP3501546A3 (de) 2011-04-21 2019-09-18 Seattle Genetics, Inc. Cystein-wirkstoff konjugate und ihre verwendung
BR112014003501B1 (pt) * 2011-08-17 2022-02-08 The Regents Of The University Of California Anticorpo humanizado que se liga especificamente à integrina alfa-v beta-8, seu uso na redução da sinalização de tgfbeta, composição farmacêutica, bem como método para detectar a presença de uma célula que expressa alfa-v beta-8
WO2014143739A2 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
WO2014144466A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
CA2934617A1 (en) 2013-12-23 2015-07-02 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (adcs) with kinesin spindle protein (ksp)
ES2897782T3 (es) 2014-09-17 2022-03-02 Merck Patent Gmbh Método de tratamiento de las enfermedades de la metástasis ósea, medicamentos para el tratamiento y método para predecir el resultado clínico del tratamiento de las enfermedades causadas por metástasis ósea
WO2016041614A1 (en) 2014-09-17 2016-03-24 Merck Patent Gmbh A method of treating solid cancers and/or metastases thereof, medicaments therefore, and a method of predicting the clinical outcome of treating solid cancers and/or metastases thereof
AU2016282723B2 (en) 2015-06-22 2021-09-23 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (ADCs) and antibody prodrug conjugates (APDCs) with enzymatically cleavable groups
CN107921288A (zh) 2015-06-23 2018-04-17 拜耳医药股份有限公司 Ksp抑制剂的靶向缀合物
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
HK1254295A1 (zh) 2015-11-23 2019-07-19 默克专利股份有限公司 用於治疗纤维化和/或纤维化病症的抗-αＶ整合素抗体
JP7251981B2 (ja) 2016-03-24 2023-04-04 バイエル ファーマ アクチエンゲゼルシャフト 酵素開裂基を有する細胞毒性活性剤のプロドラッグ
WO2017216028A1 (en) 2016-06-15 2017-12-21 Bayer Pharma Aktiengesellschaft Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies
US20190242908A1 (en) 2016-09-08 2019-08-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating nephrotic syndrome
WO2018114804A1 (de) 2016-12-21 2018-06-28 Bayer Pharma Aktiengesellschaft Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren
CA3047491A1 (en) 2016-12-21 2018-06-28 Bayer Aktiengesellschaft Prodrugs of cytotoxic active agents having enzymatically cleavable groups
KR102556826B1 (ko) 2016-12-21 2023-07-18 바이엘 파마 악티엔게젤샤프트 효소적으로 절단가능한 기를 갖는 항체 약물 접합체 (adc)
KR101961715B1 (ko) 2018-07-18 2019-03-25 (주) 삼진정밀 고효율 수처리장치
AU2019362602A1 (en) 2018-10-19 2021-06-03 Merck Patent Gmbh Abituzumab for the treatment of colorectal cancer
KR101999620B1 (ko) 2019-03-26 2019-07-12 조용진 부상슬러지 및 침전슬러지의 동시처리장치
CN113993896A (zh) * 2019-04-08 2022-01-28 比奥根Ma公司 抗整联蛋白抗体及其用途
EP4058481A1 (en) 2019-11-15 2022-09-21 Pliant Therapeutics, Inc. Compositions and methods for activation of integrins
EP4305072A4 (en) * 2021-03-09 2025-06-18 The Governing Council Of The University Of Toronto ANTIBODIES AGAINST INTEGRIN HETERODIMERS AND THEIR USES
CN117143241B (zh) * 2023-10-26 2024-02-23 迈威(上海)生物科技股份有限公司 与人整合素蛋白itgav/itgb8特异性结合的单克隆抗体
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69322860T2 (de) * 1992-04-03 1999-07-01 Genentech, Inc., South San Francisco, Calif. Antikörper gegen alpha v beta 3 integrin
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis

Also Published As

Publication number Publication date
DE69531187D1 (de) 2003-08-07
CZ328895A3 (en) 1996-09-11
HU9503638D0 (en) 1996-02-28
CA2165573A1 (en) 1996-06-21
PL182961B1 (pl) 2002-05-31
TR199501614A2 (tr) 1996-07-21
US5985278A (en) 1999-11-16
SK284932B6 (sk) 2006-02-02
SK159295A3 (en) 1996-07-03
AU710234B2 (en) 1999-09-16
CZ290477B6 (cs) 2002-07-17
NO955167D0 (no) 1995-12-19
CN1139115A (zh) 1997-01-01
PT719859E (pt) 2003-11-28
EP0719859B1 (en) 2003-07-02
SI0719859T1 (en) 2003-12-31
KR100450368B1 (ko) 2005-01-31
HU221061B1 (hu) 2002-07-29
CN1117763C (zh) 2003-08-13
JP3898245B2 (ja) 2007-03-28
BR9505980B1 (pt) 2010-02-23
NO321186B1 (no) 2006-04-03
PL311926A1 (en) 1996-06-24
HUT74828A (en) 1997-02-28
KR960022562A (ko) 1996-07-18
BR9505980A (pt) 1997-12-23
ES2202336T3 (es) 2004-04-01
DK0719859T3 (da) 2003-10-20
JPH08231597A (ja) 1996-09-10
DE69531187T2 (de) 2004-04-22
ZA9510806B (en) 1996-05-30
EP0719859A1 (en) 1996-07-03
NO955167L (no) 1996-06-21
FI956112L (fi) 1996-06-21
FI956112A0 (fi) 1995-12-19
CO4480042A1 (es) 1997-07-09
FI118536B (fi) 2007-12-14
RU2205223C2 (ru) 2003-05-27
ATE244306T1 (de) 2003-07-15
AR001778A1 (es) 1997-12-10
CA2165573C (en) 2011-03-29
AU4042195A (en) 1996-06-27

Similar Documents

Publication Publication Date Title
RU94045919A (ru) Антитела, клетки, полипептид, днк векторы, способ получения полипептида, способ получения антитела, фармацевтическая композиция
RU2252961C2 (ru) Способ получения амидированного пептида
CA2021594C (en) Antibody to human interleukin-6 receptor
CA2122732A1 (en) Multivalent antigen-binding proteins
UA40577C2 (uk) Біспецифічна молекула, що використовується для лізису пухлинних клітин, спосіб її одержання, моноклональне антитіло (варіанти), фармацевтичний препарат, фармацевтичний набір (варіанти), спосіб видалення пухлинних клітин
CA2288962A1 (en) Human monoclonal antibodies to epidermal growth factor receptor
CA2032153A1 (fr) Application de nouveaux fragments d'adn en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
CA2256308A1 (en) Antibodies to the ed-b domain of fibronectin, their construction and uses
BG102983A (en) Extramembrane protein 106 polypeptide of moraxella catarrhalis, its gene sequence and application
ZA953629B (en) Soluble polypeptidic fragments of lag-3 protein method of production thereof therapeutic composition anti-idiotype antibodies
CA2130452A1 (en) Altered antibodies, products and processes relating thereto
NZ296748A (en) Peripheral nervous system specific sodium channel proteins, DNA coding therefor, compositions and methods
HUT63652A (en) Process for producing cd44 surface protein variants, dna sequences encoding them and antibodies against them, as well as their application in diagnosis and therapy
CA2179909A1 (en) Ligand that binds fas antigen
RU2000123559A (ru) Хитинсвязывающие фрагменты хитиназы
DE69926061D1 (de) Verfahren und zusammensetzungen zur peptidsynthese (t-20)
CA2461443A1 (en) Nucleic acid and amino acid sequences encoding high-level expressor factor viii polypeptides and methods of use
EA201001190A1 (ru) Выделенное антитело, специфически связанное с полипептидом, состоящее из последовательности аминокислотных остатков
CA2343569A1 (en) Mammalian transforming growth factor beta - 9
CA2457362A1 (en) Human monoclonal rabies virus neutralizing antibodies, and methods for making and using the same
IL99079A0 (en) Protein structure of the plant toxin gelonin
WO1996023884A3 (en) Human peroxisome proliferator activated receptors
CA2058041A1 (en) Anti-igf-ii monoclonal antibody
NZ208633A (en) Dna encoding prepro hpgrf, peptides coded for, and production
IL167121A (en) Method for the preparation of growth hormone and antagonist thereof having lower levels of isoform impurities thereof